In our point, this study, which expanded the mechanism of PCSK9 inhibition on atherosclerosis therapy, demonstrated that the constructed (Lipo + M)@E NPs provide a promising option for the treatment of atherosclerosis. The gene discussed is PCSK9; the disease is atherosclerosis.